Algernon Pharmaceuticals Inc.

AGN on CSEToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.12CAN 0.00/0.00%77,0000.10 / 0.555.44 M
BTHCF on OTCQBToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.09US 0.00/0.00%00.07 / 0.404.42 M

Contact Information

Algernon Pharmaceuticals Inc.

Headquarters:
700 West Pender Street, Suite 915
Vancouver, British Columbia
Canada, V6C 1G8
Tel: 604-646-1553
Email: Send a message
Website: Visit website
For more information...
Lead: Barry Mire

The Algernon business model is to repurpose safe, approved generic drugs that are not available in the US or Europe, screen them in globally accepted animal models for new diseases, file new intellectual property rights and then move them into an off label phase II trial in the country where they are currently approved. Once a signal is established in a human trial, the company will begin to advance the drug through a USFDA registration.

The Company is preparing multiple compounds for phase II trials for the disease areas of non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), chronic kidney disease  (CKD) and idiopathic pulmonary fibrosis (IPF).

Christoper J. Moreau - Chief Executive Officer

Mark Williams, PhD, MBA - Chief Science Officer

Michael Sadhra, CA - Chief Financial Officer & Director

Raj Attariwala, MD, PhD. - Director

Michael Sadhra, CA - Chief Financial Officer & Director

David Levina - Director

Stock Information

Company Overview

The Algernon business model is to repurpose safe, approved generic drugs that are not available in the US or Europe, screen them in globally accepted animal models for new diseases, file new intellectual property rights and then move them into an off label phase II trial in the country where they are currently approved. Once a signal is established in a human trial, the company will begin to advance the drug through a USFDA registration.

The Company is preparing multiple compounds for phase II trials for the disease areas of non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), chronic kidney disease  (CKD) and idiopathic pulmonary fibrosis (IPF).

Management

Christoper J. Moreau - Chief Executive Officer

Mark Williams, PhD, MBA - Chief Science Officer

Michael Sadhra, CA - Chief Financial Officer & Director

Board of Directors

Raj Attariwala, MD, PhD. - Director

Michael Sadhra, CA - Chief Financial Officer & Director

David Levina - Director

Contact Information

Headquarters:
700 West Pender Street, Suite 915
Vancouver, British Columbia
V6C 1G8, Canada
Telephone: 604-646-1553
Email: Send a message
Website: Visit website